Nevirapine‑Associated Stevens‑Johnson Syndrome and Toxic Epidermal Necrolysis: Evidence‑Based Guidance

Epidemiology and Relative Risk

Guidelines published in Annals of Internal Medicine state that among NNRTIs, nevirapine is linked to the highest frequency and severity of skin rash, and that Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) mandates immediate and permanent discontinuation of the drug. High‑quality evidence supports this recommendation. 1
According to British Journal of Pharmacology guidelines, SJS occurs in approximately 0.37 % of patients receiving nevirapine, a rate markedly greater than that observed with other antiretroviral agents. Observational data underpin this estimate. 2

The median interval from nevirapine initiation to onset of a severe cutaneous eruption is 11 days, with about two‑thirds of cases arising during the initial dosing period; however, reactions have been reported from 10 days up to 240 days after starting therapy. Case‑control data provide the basis for these timing estimates. 1

Female patients experience up to a seven‑fold increased risk of developing grade 3 or 4 skin rashes compared with male patients when treated with nevirapine. Epidemiologic analysis supports this gender‑specific risk. 1

Both Annals of Internal Medicine and British Journal of Pharmacology advise against the use of prophylactic corticosteroids or antihistamines at nevirapine initiation, as these strategies have not prevented SJS/TEN and may actually raise rash incidence. Randomized and observational studies inform this guidance. 1, 2

Immediate, permanent cessation of nevirapine (or any offending NNRTI) is mandatory when SJS or TEN is suspected. Clinical guideline consensus underlies this directive. 1
Re‑exposure to nevirapine after a severe hypersensitivity reaction is strongly contraindicated, because subsequent reactions are typically more rapid and severe. Pharmacovigilance data support this recommendation. 2

Efavirenz, another NNRTI, is associated with rash in 10–17 % of patients, though the incidence of severe reactions (SJS/TEN) is considerably lower than with nevirapine. Pharmacologic safety reviews provide these figures. 2
Abacavir requires permanent discontinuation if a hypersensitivity reaction occurs (as per Praxis Medical Insights). Clinical practice guidelines dictate this action. 3

Presence of mucosal involvement, skin detachment/epidermal sloughing, and fever > 39 °C are key signs indicating severe hypersensitivity that warrants hospitalization and urgent drug withdrawal. Expert consensus informs this clinical assessment. 3